ReviewPharmaceutical medicine2023
Using Patient Perspectives to Inform Better Clinical Trial Design and Conduct: Current Trends and Future Directions.
Review in Pharmaceutical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Evaluating the utility of a patient and public involvement and engagement (PPIE) end-of-trial event to re-engage with cell-based therapy participants.Regenerative medicine · 2025Trial
- The Healing Through Ongoing Psychological Empowerment Telehealth Intervention With Two Spirit, Transgender, and Nonbinary Clients of Color in the United States: Open Clinical Trial Feasibility and Implementation Analysis.JMIR formative research · 2025Trial
- Why involvement remains fragile: a qualitative comparison of principal investigators' and patient organisations' perspectives in Italy.Research involvement and engagement · 2026Article
- Article
- Advancing the Science of Patient Input in Drug Research and Development.Journal of participatory medicine · 2026Article
- Review
- Strategies for optimizing clinical trial recruitment: perspectives among patients with breast cancer.Cancer causes & control : CCC · 2026Article
- PAtient-Centric epilepsy clinical trIal model For Improved health outcomes using Cannabidiol (PACIFIC study)-a methodology for developing patient-centred clinical trials in rare epilepsy syndromes.BMC medical research methodology · 2026Article
- Participant Experience, Acceptability and Feasibility of Virtual and Digitally Supported Visits in a Phase IIa COPD Trial.Journal of patient experience · 2026Article
- Clinician, patient, and carer views on neuromodulation for epilepsy: is there rationale for a randomised controlled trial of VNS vs. DBS?Brain & spine · 2026Article
- New pharmacotherapies for the erythropoietic protoporphyrias: an analysis of trial protocols from a patient perspective.Orphanet journal of rare diseases · 2025Article
- Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosedFuture oncology (London, England) · 2025Article
- Life after hepatorenal syndrome: unraveling quality of life, psychological distress, and treatment preferences.BMC palliative care · 2025Article
- Establishing a core outcome set for creatine transporter deficiency and guanidinoacetate methyltransferase deficiency.Orphanet journal of rare diseases · 2025Article
- Clinical Trial Simulation in Geographic Atrophy: Patient, Caregiver, and Trial Site Staff Perspectives.Ophthalmology and therapy · 2025Article
- Clinical Trial Simulation in Diabetic Retinopathy: Insights from Patients and Site Staff.Ophthalmology and therapy · 2025Article
- Integrating Sustainability Pillars Into Trial Design Decision-Making: Results of an International Survey.Clinical and translational science · 2025Article
- Article
- The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment.BMC complementary medicine and therapies · 2025Article
- Unmasking Racial, Ethnic, and Socioeconomic Disparities in United States Chordoma Clinical Trials: Systematic Review.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The approach to patient engagement (PE) in drug development has changed rapidly due to many factors, including the complexity of innovative drugs and the need to demonstrate outcomes of relevance to patients, the desire to show 'value add' of PE, and the pandemic-related changes to how clinical trials are run, e.g., decentralised studies. In parallel, there have been changes in technology-assisted ways of running clinical trials, capturing patient health outcomes and preferences, an increasing societal demand for diversity and inclusion, and efforts to improve clinical trial efficiency, transparency, and accountability. Organisations are beginning to monitor PE activities and outcomes more effectively to learn and inform future PE strategies. As a result, these factors are facilitating the incorporation of patients' lived experience, preferences and needs into the design and running of clinical trials more than ever before. In this paper, the authors reflect upon these last few years, the emerging trends and their drivers, and where we may expect PE in clinical research to progress in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.